Privi Speciality Chemicals Capital Structure Change
SBI Mutual Fund sold 18,400 shares of Privi Speciality Chemicals Ltd via open market, reducing its stake from 7.3905% to 7.3434%.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements
SBI Mutual Fund sold 18,400 shares of Privi Speciality Chemicals Ltd via open market, reducing its stake from 7.3905% to 7.3434%.
Privi Speciality Chemicals announced an NCLT-convened meeting of equity shareholders for October 27, 2026, to consider the proposed Scheme of Amalgamation involving two transferor companies.
Privi reports 19.22% revenue growth and steady 24% EBITDA margins. Management maintains a confident outlook on expansion despite gross margin compression from high raw material costs compared to last year's low-cost base.
Privi reported strong Q1 FY27 results with 20.01% YoY revenue growth. Strategy focuses on '5k | 1k' vision via capacity expansion and higher-value specialty molecules.
Privi Speciality Chemicals Ltd reported revenue from operations of ₹666.2 Cr (+19.2% YoY) and net profit of ₹82.8 Cr (+43.7% YoY) for Q1 FY27.
Privi reported strong FY26 performance with 22% revenue growth and 25.76% EBITDA margins, driven by volume growth and improved product mix.
Privi delivered strong FY26 performance with 22% revenue growth and 25%+ margins. Management is pivoting from a '5k revenue' goal to a more aggressive long-term trajectory via high-value specialty molecules and backward integration.
Privi Speciality Chemicals Ltd reported revenue from operations of ₹721.5 Cr (+17.6% YoY) and net profit of ₹94.1 Cr (+47.0% YoY) for Q4 FY26.